This is in line with observations on the use of mTOR inhibitors (1%) from the multicenter TSC Natural History Database, which included patients between 2006 and 2014 [31] and interim analysis of the TOSCA study in 2015 reporting everolimus treatment in 7.7% of patients with focal seizures and 5.5% with infantile spasms [30]. The gene discussed is MTOR; the disease is tuberous sclerosis.